APA

Leonardi S., Rao S. V., Harrington R. A., Bhatt D. L., Gibson C. M., Roe M. T., Kochman J., Huber K., Zeymer U., Madan M., Gretler D. D., McClure M. W., Paynter G. E., Thompson V. & Welsh R. C. (20100817). Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). : American heart journal.

Chicago

Leonardi Sergio, Rao Sunil V, Harrington Robert A, Bhatt Deepak L, Gibson C Michael, Roe Matthew T, Kochman Janusz, Huber Kurt, Zeymer Uwe, Madan Mina, Gretler Daniel D, McClure Matthew W, Paynter Gayle E, Thompson Vivian and Welsh Robert C. 20100817. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). : American heart journal.

Harvard

Leonardi S., Rao S. V., Harrington R. A., Bhatt D. L., Gibson C. M., Roe M. T., Kochman J., Huber K., Zeymer U., Madan M., Gretler D. D., McClure M. W., Paynter G. E., Thompson V. and Welsh R. C. (20100817). Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). : American heart journal.

MLA

Leonardi Sergio, Rao Sunil V, Harrington Robert A, Bhatt Deepak L, Gibson C Michael, Roe Matthew T, Kochman Janusz, Huber Kurt, Zeymer Uwe, Madan Mina, Gretler Daniel D, McClure Matthew W, Paynter Gayle E, Thompson Vivian and Welsh Robert C. Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). : American heart journal. 20100817.